Most Read Articles
3 days ago
Children with high dental anxiety are more likely to develop dental diseases, which, in turn, negatively affect the family’s quality of life, a recent study has found.
2 days ago
Exposure to corticosteroids in patients with autoimmune hepatitis (AIH) appears to contribute to increased risks of cataract, diabetes and bone fractures, a study has found. Notably, the fracture risk is elevated at low doses, while the risk of adverse events overall is dose-dependent and is reversible.
6 days ago
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
3 days ago
Supplementation with oral nano vitamin D appears to moderate disease activity and severity grade of patients with active ulcerative colitis (UC), suggests a study, adding that this association is more evident in those achieving a target vitamin D level of 40 ng/mL.

Ustekinumab effective for IBD with concomitant psoriasis, psoriatic arthritis

03 Jul 2019
Crohn’s is not the end of the world, as Kathleen Baker’s silver medal proves

Ustekinumab, delivered subcutaneously, is effective for patients with inflammatory bowel disease (IBD) receiving concomitant treatment for dermatological or rheumatological conditions, a recent study has found.

Researchers conducted a multicentre, retrospective analysis of 70 IBD patients (median age, 41.75 years; 45 percent female; 91.4 percent Crohn’s disease) who were initiated on ustekinumab for concomitant active psoriasis or psoriatic arthritis. The primary study endpoint was overall persistence of ustekinumab, defined as therapy maintenance due to sustained clinical benefit.

The median time on ustekinumab was 10.7 months. Twelve patients (17.1 percent) withdrew from the medication, all of whom had CD. Median time to withdrawal was 7.4 months. Half of the withdrawals were due to the lack of benefit for the skin or joint disease, four due to lack of benefit for IBD, and two due to adverse events.

At baseline, 56 patients had active disease. At the last follow-up after ustekinumab treatment, majority of these participants (60.7 percent; n=34) were in clinical remission. The cumulative probabilities of achieving remission at 6 and 9 months were 84.7 percent and 63.9 percent, respectively.

Disaggregating according to comorbid conditions did not meaningfully change the results. Ustekinumab induced clinical remission in majority of patients with either psoriasis (82.2 percent; 37 of 45) or psoriatic arthritis (60 percent; 15 of 25).

Ustekinumab likewise had a favourable safety profile. Only 10 cases of adverse events were reported in nine participants. Three adverse events needed emergency care: acute intestinal obstruction, dehydration due to acute gastroenteritis and acute renal colic.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
Children with high dental anxiety are more likely to develop dental diseases, which, in turn, negatively affect the family’s quality of life, a recent study has found.
2 days ago
Exposure to corticosteroids in patients with autoimmune hepatitis (AIH) appears to contribute to increased risks of cataract, diabetes and bone fractures, a study has found. Notably, the fracture risk is elevated at low doses, while the risk of adverse events overall is dose-dependent and is reversible.
6 days ago
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
3 days ago
Supplementation with oral nano vitamin D appears to moderate disease activity and severity grade of patients with active ulcerative colitis (UC), suggests a study, adding that this association is more evident in those achieving a target vitamin D level of 40 ng/mL.